The French company Sanofi is examining the possibility of acquiring the American biopharmaceutical company Insmed with a market value of approximately 26.6 billion dollars, reports Bloomberg. During the last 12 months, Insmed's share fell by about 40%. The deal may become the largest in the sector in a few years, but the parties are still negotiating and a decision has not yet been made.